Loading…
MAFLD: How is it different from NAFLD?
"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable eas...
Saved in:
Published in: | Clinical and molecular hepatology 2023, 29(0), , pp.17-31 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063 |
---|---|
cites | cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063 |
container_end_page | S31 |
container_issue | Suppl |
container_start_page | S17 |
container_title | Clinical and molecular hepatology |
container_volume | 29 |
creator | Gofton, Cameron Upendran, Yadhavan Zheng, Ming-Hua George, Jacob |
description | "Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research. |
doi_str_mv | 10.3350/cmh.2022.0367 |
format | article |
fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10184876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_550566d34434435f859cfe1bf0c5806e</doaj_id><sourcerecordid>3125511976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</originalsourceid><addsrcrecordid>eNpVUU1LAzEUDKKoaI9eZUHwIGx9-dysFyl-tVAVRMFbSPOhW9tGs1vFf2-2tWJD4IXMvMm8DEIHGLqUcjg109cuAUK6QEWxgXYJkUVOJH_eXJ0LIndQp67HkFYBhJd0G-1QwRgtidhFx7e96-HlWdYPX1lVZ1WT2cp7F92syXwM0-yuxc_30ZbXk9p1fuseerq-erzo58P7m8FFb5gbJlmTe4GdJZYBF5yDd544o7WQpsDSageUO8sLaw0fMSIExgZ86RPoGQUPgu6hk6XuLHr1ZioVdLWoL0G9RdV7eBwoDFgyWbTkwZJsgx6r91hNdfxedCwuQnxROjaVmTiV3HAhLE1jp8295KXxDo88GC5BuKR1vtR6n4-mzpo0f9STNdF1ZFa9JlOfyQ2QsmRlUjj6VYjhY-7qRo3DPM7SbymKCecYlwvP-ZJlYqjr6PzfExhUm6lKmao2U9VmmviH_339sVcJ0h_yrJg_</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125511976</pqid></control><display><type>article</type><title>MAFLD: How is it different from NAFLD?</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</creator><creatorcontrib>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</creatorcontrib><description>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</description><identifier>ISSN: 2287-2728</identifier><identifier>EISSN: 2287-285X</identifier><identifier>DOI: 10.3350/cmh.2022.0367</identifier><identifier>PMID: 36443926</identifier><language>eng</language><publisher>Korea (South): Korean Association for the Study of the Liver</publisher><subject>Alcohol use ; Gastroenterology ; High density lipoprotein ; Humans ; Liver cirrhosis ; Liver diseases ; mafld ; mafld vs. nafld ; Metabolic Diseases - classification ; Metabolic Diseases - diagnosis ; Metabolism ; nafld ; Name changes ; Non-alcoholic Fatty Liver Disease - classification ; Non-alcoholic Fatty Liver Disease - diagnosis ; Overweight ; Patients ; Perceptions ; Review ; Risk factors ; Terminology ; 내과학</subject><ispartof>Clinical and Molecular Hepatology, 2023, 29(0), , pp.17-31</ispartof><rights>2023. This work is published under http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023 by The Korean Association for the Study of the Liver 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</citedby><cites>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</cites><orcidid>0000-0002-0913-7180</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029949/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3125511976?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36443926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002933075$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Gofton, Cameron</creatorcontrib><creatorcontrib>Upendran, Yadhavan</creatorcontrib><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><title>MAFLD: How is it different from NAFLD?</title><title>Clinical and molecular hepatology</title><addtitle>Clin Mol Hepatol</addtitle><description>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</description><subject>Alcohol use</subject><subject>Gastroenterology</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>mafld</subject><subject>mafld vs. nafld</subject><subject>Metabolic Diseases - classification</subject><subject>Metabolic Diseases - diagnosis</subject><subject>Metabolism</subject><subject>nafld</subject><subject>Name changes</subject><subject>Non-alcoholic Fatty Liver Disease - classification</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Overweight</subject><subject>Patients</subject><subject>Perceptions</subject><subject>Review</subject><subject>Risk factors</subject><subject>Terminology</subject><subject>내과학</subject><issn>2287-2728</issn><issn>2287-285X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVUU1LAzEUDKKoaI9eZUHwIGx9-dysFyl-tVAVRMFbSPOhW9tGs1vFf2-2tWJD4IXMvMm8DEIHGLqUcjg109cuAUK6QEWxgXYJkUVOJH_eXJ0LIndQp67HkFYBhJd0G-1QwRgtidhFx7e96-HlWdYPX1lVZ1WT2cp7F92syXwM0-yuxc_30ZbXk9p1fuseerq-erzo58P7m8FFb5gbJlmTe4GdJZYBF5yDd544o7WQpsDSageUO8sLaw0fMSIExgZ86RPoGQUPgu6hk6XuLHr1ZioVdLWoL0G9RdV7eBwoDFgyWbTkwZJsgx6r91hNdfxedCwuQnxROjaVmTiV3HAhLE1jp8295KXxDo88GC5BuKR1vtR6n4-mzpo0f9STNdF1ZFa9JlOfyQ2QsmRlUjj6VYjhY-7qRo3DPM7SbymKCecYlwvP-ZJlYqjr6PzfExhUm6lKmao2U9VmmviH_339sVcJ0h_yrJg_</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Gofton, Cameron</creator><creator>Upendran, Yadhavan</creator><creator>Zheng, Ming-Hua</creator><creator>George, Jacob</creator><general>Korean Association for the Study of the Liver</general><general>The Korean Association for the Study of the Liver</general><general>대한간학회</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-0913-7180</orcidid></search><sort><creationdate>20230201</creationdate><title>MAFLD: How is it different from NAFLD?</title><author>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alcohol use</topic><topic>Gastroenterology</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>mafld</topic><topic>mafld vs. nafld</topic><topic>Metabolic Diseases - classification</topic><topic>Metabolic Diseases - diagnosis</topic><topic>Metabolism</topic><topic>nafld</topic><topic>Name changes</topic><topic>Non-alcoholic Fatty Liver Disease - classification</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Overweight</topic><topic>Patients</topic><topic>Perceptions</topic><topic>Review</topic><topic>Risk factors</topic><topic>Terminology</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gofton, Cameron</creatorcontrib><creatorcontrib>Upendran, Yadhavan</creatorcontrib><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><collection>Korean Citation Index</collection><jtitle>Clinical and molecular hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gofton, Cameron</au><au>Upendran, Yadhavan</au><au>Zheng, Ming-Hua</au><au>George, Jacob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAFLD: How is it different from NAFLD?</atitle><jtitle>Clinical and molecular hepatology</jtitle><addtitle>Clin Mol Hepatol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>29</volume><issue>Suppl</issue><spage>S17</spage><epage>S31</epage><pages>S17-S31</pages><issn>2287-2728</issn><eissn>2287-285X</eissn><abstract>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</abstract><cop>Korea (South)</cop><pub>Korean Association for the Study of the Liver</pub><pmid>36443926</pmid><doi>10.3350/cmh.2022.0367</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-0913-7180</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2287-2728 |
ispartof | Clinical and Molecular Hepatology, 2023, 29(0), , pp.17-31 |
issn | 2287-2728 2287-285X |
language | eng |
recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_10184876 |
source | Publicly Available Content Database; PubMed Central |
subjects | Alcohol use Gastroenterology High density lipoprotein Humans Liver cirrhosis Liver diseases mafld mafld vs. nafld Metabolic Diseases - classification Metabolic Diseases - diagnosis Metabolism nafld Name changes Non-alcoholic Fatty Liver Disease - classification Non-alcoholic Fatty Liver Disease - diagnosis Overweight Patients Perceptions Review Risk factors Terminology 내과학 |
title | MAFLD: How is it different from NAFLD? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A40%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAFLD:%20How%20is%20it%20different%20from%20NAFLD?&rft.jtitle=Clinical%20and%20molecular%20hepatology&rft.au=Gofton,%20Cameron&rft.date=2023-02-01&rft.volume=29&rft.issue=Suppl&rft.spage=S17&rft.epage=S31&rft.pages=S17-S31&rft.issn=2287-2728&rft.eissn=2287-285X&rft_id=info:doi/10.3350/cmh.2022.0367&rft_dat=%3Cproquest_nrf_k%3E3125511976%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3125511976&rft_id=info:pmid/36443926&rfr_iscdi=true |